INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
THE MYWEIGHTLAB DRUG TRACKER

Weight-Loss Drug Tracker

Evidence-led profiles of weight-management medicines: mechanisms, indications, regulatory status, and the questions still being studied.

Approval depends on the product, indication, and country. These profiles are informational and do not recommend prescribing or self-medication.

Swipe or scroll horizontally to compare all columns. With a keyboard, focus the table and use the arrow keys.

Selected medicines: regulatory facts are product-, indication- and jurisdiction-specific
Drug / mechanismDevelopment evidenceUS FDAEU EMAChecked / sources
RetatrutideGIP, GLP-1 and glucagon receptor agonistPhase 3 evidence; TRIUMPH-1 registry completedFDA states retatrutide is not a component of an FDA-approved drug. Trial completion and published results do not establish marketing approval.FDAEU marketing authorisation has not been verified in the reviewed sources. A trial, publication or pediatric-development plan is not an authorisation.NLM / original NEJM trial abstractNLM / original NEJM trial abstract
CagriSemaAmylin analogue plus GLP-1 receptor agonistPhase 3 evidence; US submission announced; sponsor still calls it investigationalNovo Nordisk announced a US application in December 2025 and still called CagriSema investigational on 30 September 2026. An application is not FDA approval.Novo NordiskNovo NordiskEU marketing authorisation has not been verified in the reviewed sources. A trial, publication or pediatric-development plan is not an authorisation.NLM / original NEJM trial abstractNovo Nordisk
OrforglipronNonpeptide small-molecule GLP-1 receptor agonistUS approved product; Phase 3 clinical evidence; EU assessment latest verified recordFDA approved Foundayo (orforglipron) on 1 April 2026 for adult weight management with diet and physical activity, subject to product-specific indications and restrictions.FDAThe 14–17 September 2026 CHMP agenda lists orforglipron among applications with outstanding issues. A subsequent EU marketing authorisation has not been verified.EMANLM / original NEJM trial abstractNLM / original NEJM trial abstract
SurvodutideGLP-1 and glucagon receptor agonistPhase 3 clinical evidence; investigational in the cited paperFDA approval has not been verified. Its August 2026 enforcement letter identifies a marketed survodutide product as unapproved; this product-specific enforcement record is not an exhaustive global regulatory search.FDAEU marketing authorisation has not been verified in the reviewed sources. A trial, publication or pediatric-development plan is not an authorisation.NLM / original NEJM trial abstractNLM / original NEJM trial abstract
SemaglutideGLP-1 receptor agonistApproved product-specific uses; continuing clinical researchWegovy has FDA-approved formulations for specified weight-management uses. The cited 2026 letter approves a new injection presentation and aligned labeling; this does not extend every indication to every semaglutide brand.FDAEMA records EU authorisation of Wegovy for specified weight-management populations, with different restrictions for injections and tablets.EMANLM / original NEJM trial abstractNLM / original NEJM trial abstract
TirzepatideGIP and GLP-1 receptor agonistApproved product-specific uses; continuing clinical researchZepbound is FDA-approved for specified adult weight-management use and moderate-to-severe obstructive sleep apnea in adults with obesity; labels and population restrictions apply.FDAFDAEMA records EU authorisation of Mounjaro for specified diabetes uses and adult weight management. US and EU product indications remain separate.EMANLM / original NEJM trial abstractNLM / original NEJM trial abstract

A development stage does not establish approval. Not verified means the reviewed evidence did not establish that fact; it is not a comprehensive worldwide authorization search.

A genuine Mounjaro KwikPen containing tirzepatide, with its original German-language label.
Genuine Mounjaro KwikPen in a German-language presentation. Original product photograph retained within an adjusted editorial frame. Branding and available products vary by country; the pictured dose is not dosing advice. © Raimond Spekking / CC BY-SA 4.0 (via Wikimedia Commons) Source: https://commons.wikimedia.org/wiki/File:Lilly_mounjaro_KwikPen_Tirzepatid_5_mg_per_dose_rate-9442.jpg License: https://creativecommons.org/licenses/by-sa/4.0. Layout and size adjusted.
MEDICINE PROFILE

Tirzepatide

tirzepatide

GIP and GLP-1 receptor agonist

Administration
Subcutaneous injection
FDA status
Zepbound is FDA-approved for specified adult weight-management uses and moderate-to-severe obstructive sleep apnea in adults with obesity. Product-label restrictions apply.
Evidence checked
2026-10-03
Read the profile
Single conceptual survodutide carton labeled Illustration and Investigational.
Conceptual SURVODUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.
MEDICINE PROFILE

Survodutide

survodutide

GLP-1 and glucagon receptor agonist

Administration
Subcutaneous injection in clinical trials
FDA status
FDA approval has not been verified. An FDA warning letter dated 24 August 2026 identifies marketed survodutide products as unapproved. October Phase 3 publication is not approval evidence.
Evidence checked
2026-10-03
Read the profile
A single official Wegovy 1.5 mg oral semaglutide carton in an outside-US presentation.
Official Wegovy oral-tablet carton in the outside-US presentation supplied by Novo Nordisk. Packaging varies by market; this image is not dosing advice. Image: Novo Nordisk. Official Wegovy media kit: https://www.novonordisk.com/news-and-media/wegovy-media-kit.html
MEDICINE PROFILE

Semaglutide

semaglutide

GLP-1 receptor agonist

Administration
Wegovy: subcutaneous injection or oral tablet, depending on the approved formulation
FDA status
Wegovy formulations are FDA-approved for specified uses. Higher-dose Wegovy HD was approved on 19 March 2026. Approval is formulation- and indication-specific; this record does not extend every use to all semaglutide brands.
Evidence checked
2026-10-03
Read the profile
Single conceptual retatrutide carton labeled Illustration and Investigational.
Conceptual RETATRUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.
MEDICINE PROFILE

Retatrutide

retatrutide

GIP, GLP-1 and glucagon receptor agonist

Administration
Subcutaneous injection in clinical trials
FDA status
FDA states retatrutide is not a component of an FDA-approved drug; current sponsor sources call it investigational. Trial publication does not establish routine marketing approval.
Evidence checked
2026-10-03
Read the profile
A single official Foundayo orforglipron 0.8 mg bottle in its original US presentation.
Official Foundayo product photograph showing an orforglipron bottle in its US presentation. The pictured dose and packaging are not dosing advice. Image: Eli Lilly and Company. Official Foundayo media kit: https://www.lilly.com/news/media/foundayo
MEDICINE PROFILE

Orforglipron

orforglipron

Nonpeptide small-molecule GLP-1 receptor agonist

Administration
Oral tablet in the approved US Foundayo product
FDA status
FDA approved Foundayo on 1 April 2026 for specified adult weight-management use alongside a reduced-calorie diet and increased activity. Current label restrictions apply.
Evidence checked
2026-10-03
Read the profile
Single conceptual cagrisema carton labeled Illustration and Investigational.
Conceptual CagriSema carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.
MEDICINE PROFILE

CagriSema

cagrilintide–semaglutide

Amylin analogue cagrilintide combined with GLP-1 receptor agonist semaglutide

Administration
Subcutaneous injection in clinical trials
FDA status
Sponsor announced an FDA application on 18 December 2025 and still described CagriSema as investigational on 30 September 2026. Subsequent FDA approval has not been verified.
Evidence checked
2026-10-03
Read the profile
FROM PROFILE TO PRACTICE

Find the answer you need

THE MYWEIGHTLAB BRIEFING

Weight-Loss Intelligence, Without the Noise

The most important developments in obesity drugs, nutrition, training and weight-management science — curated and explained.

Free to join. Confirm by email; unsubscribe at any time.

Cookie policy